RankingsPricing
  1. US-listed companies
  2. TEVA PHARMACEUTICAL INDUSTRIES LTD
  3. Financials
  4. Stock-based compensation

TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA

Market cap
$27.8B
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 2024123+1.65%
Dec 31, 2023121-2.42%
Dec 31, 2022124+4.20%
Dec 31, 2021119-7.75%
Dec 31, 2020129+8.40%
Dec 31, 2019119-23.23%
Dec 31, 2018155+16.54%
Dec 31, 2017133+7.26%
Dec 31, 2016124+5.98%
Dec 31, 2015117+23.16%
Dec 31, 201495+48.44%
Dec 31, 201364-21.95%
Dec 31, 201282-9.89%
Dec 31, 201191+13.75%
Dec 31, 201080

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)